glp-1 news past 2 days Receptor Agonist Market Growth Analysis GLP-1 Pipeline Update: August 2025

Three core barriers prevent broader and faster progress: medication cost, medication side effects, and the lack of sustainable behavior change

Davies said several GLP-1/glucagon dual agonists have moved on to phase 2 or phase 3 trials, including survodutide (Boehringer Ingelheim), efinopegdutide (Hanmi Pharmaceutical), mazdutide (Eli Lilly and Innovent) and pemvidutide (Altimmune)

1.51 g 2.7%

The Longevity Approach to Aesthetics for Men in NYC Longevity-based aesthetics prioritizes skin quality, muscle tone, metabolic health, and preventative care

An argument can be made for early treatment in borderline cases, especially in patients with the identified high-risk characteristics for retinopathy progression with GLP-1/GIP agonist use ( Table 2 )